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Methylmalonic and propionic acidemia are two organic acidemias. These inborn errors of 
amino acid metabolism have been studied extensively for decades. Through clinical and 
scientific study, researchers have been able to elucidate the biochemistry and cell biology 
that underlies these two diseases. This review gives a comprehensive overview of the 
history of the disease, as well as a scientific description of the related enzymes, cofactors, 
and genetic basis for disease. In conclusion, clinical manifestations and treatments are 
described, and recommendations for further study are provided. 
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Branch chain amino acid metabolism has been a topic of study for researchers for 
decades. In studying branch chain amino acid metabolism, scientists have found many 
inborn errors of metabolism that cause disease. In examining both the pathways and the 
disease states, a full picture of the biochemistry behind branch chain amino acid 
metabolism can be elucidated. 
Methylmalonic acidemia and propionic acidemia are two diseases that occur as a 
result of inborn errors of branch chain amino acid metabolism.  Propionic acidemia was 
first described by Childs1 in 1961, and was originally called ketotic hyperglycinemia. 
With continued research, it was discovered that the disease was an error of propionate 
metabolism that often, but not always, had ketosis and hyperglycinemia as clinical 
features. The next year, Cox and White2 described methylmalonic acidemia as a 
metabolic error that manifests in some patients when serum cobalamin (B12) levels are 
low. Cox and White also showed that cobalamin administration would alleviate 
methymalonic acid levels in a single patient. Today it is understood that this patient did 
not have classical methylmalonic acidemia where the inborn error is found in 
methylmalonyl-CoA mutase, rather, he had a defect in cobalamin synthesis. Much work 
has been done in the last decades to understand the biochemical, genetic, and clinical 




Propionate metabolism has been elucidated by studying animal and human tissues, 
primarily liver and kidney. In 1955, Lardy3 showed that propionate is converted to 
succinate by enzymes in liver mitochondria in a range of animals. That same year, it was 
also reported by two groups that methylmalonate is an intermediate in propionate 
metabolism.4,5 Additional studies confirmed that methylmalonyl-CoA was converted to 
succinyl-CoA.6  Two years later, Flavin’s group described a more complete sequence of 
propionate metabolism that included appropriate CoA esters.7 
 
Methylmalonate as an intermediate was further shown to have two isomeric forms. In 
19648, it was shown that the “D” form of methylmalonyl-CoA was formed directly from 
propionyl-CoA carboxylase. However, two years later, Sprecher9 reported that 
methylmalonyl-CoA must be converted to its L-isoform in order to be converted to 
succinyl-CoA by methylmalonyl-CoA mutase. Meanwhile, Mazumder had isolated and 
purified methylmalonyl-CoA racemase from sheep liver, and had also determined that the 
racemization occurred by an α-hydrogen atom shift.10 Thus, the components of the 
pathway were completely described. 
 




Propionate is found in small quantities in the human body. It is an important part of 
amino acid metabolism, and is part of a pathway that eventually feeds into the citric acid 
cycle via succinyl-CoA. Propionate comes from three important sources in the body: 
anaerobic gut bacteria, branch chain amino acid metabolism, and β-oxidation of odd-
numbered long chain fatty acids. In methylmalonic acidemia and propionic acidemia 
patients, the proportion of propionate generated from each source is somewhere around 
50% from amino acids, and either 20%/30% bacteria/fatty acids11 or 25%/25% 
bacteria/fatty acids.12  
 
Childs1 first described the amino acids that may play a role in producing propionyl-CoA. 
His studies implicated leucine, and to a lesser degree isoleucine, valine, and threonine.  
For methylmalonic acidemia, Rosenberg26 implicated isoleucine and valine as disease 
causing. Interestingly it was 1975 before the full biochemical pathway was determined 
that showed that propionate was an intermediate of valine metabolism.13, 14 It is now 
known definitively that isoleucine and valine metabolism are the leading amino acids that 
contribute to disease via propionyl-CoA formation. 
4 
ENZYMES 
During the period that the biochemical pathways were being elucidated, the enzymes 
responsible for the reactions within the pathways were also being discovered, isolated, 
and purified.   
Propionyl-CoA carboxylase was first described by Tietz15 in 1959, where he 
described the mechanism of this enzyme, which included performing both CO2 activation 
and carboxylation activites. Later, propionyl-CoA carboxylase was first crystallized in 
pig’s heart and also shown to bind biotin.16 Studies crystallizing the enzyme from bovine 
kidney17 and human liver confirmed this.18, 19 Propionyl-CoA carboxylase is composed of 
2 non-identical subunit protomers17, the larger of which binds biotin.15, 17 The human 
enzyme is 750-800 kDalton in its native form,20 and the mass of each subunit is 72 
kDalton and 56 kDalton for the α and β subunits, respectively.19  In conjunction with this 
data, it was also shown that the homologous enzyme in the bacterium Mycobacterium 
smegmatis has a (αβ)6 configuration.21 All of this evidence points to an (αβ)6 
configuration for the human enzyme as well. 
The CO2 fixation and the carboxylase activity of propionyl-CoA carboxylase 
happen in tandem. ATP is required and potassium22 stimulates the first step which is 
forming a carboxybiotin-apoenzyme complex. The resulting complex reacts directly with 
the biotin in order to transfer the carboxyl group, forming methylmalonyl-CoA.23 The 
biotin is directly linked to a well-defined biotin binding site on the α-subunit.24  
Methylmalonyl-CoA mutase was described in 1959, as an enzyme analogous to β-
methylaspartate in bacteria.25 It was also shown to require B12 (in the form 
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adenosylcobalamin) at this time.26 Isolation and purification of methylmalonyl-CoA 
mutase from human placenta showed that it is a dimmer composed of identical subunits.27 
Methylmalonyl-CoA mutase is covalently bonded to B12, which is a fact confirmed by 
isolation of methylmalonyl-CoA mutase from human liver.28 It was demonstrated that 
activity of the enzyme was stimulated by anions, and inhibited by cations.  In addition, 
hydroxocobalamin, a form of cobalamin, was found to be an irreversible and competitive 
inhibitor of the enzyme.29 The enzyme is a homodimer with the molecular mass of 145 
kDaltons, and each subunit binds one cobalamin. This is in contrast to the 
methylmalonyl-CoA mutase found in Propionibacterium shermanii, which is made of 2 
non-identical subunits, where the α-subunit binds adenosylcobalamin. The human form 
of the enzyme appears to have unequal binding sites, as it has been shown to have 
complex kinetics.29 
The mechanism by which methylmalonic-CoA mutase works is by an 
intramolecular shift of the CoA carboxyl group.30, 31 This shift occurs via a pair of free 
radicals formed by adenosylcobalamin.32 Electron paramagnetic resonance studies 
confirmed this mechanism by showing the radical intermediates that are formed from the 
hemolytic dissociation of the adenosylcobalamin cobalt-carbon bond.33 
Propionibacterium shermanii also showed radical intermediates by electron paramagnetic 
resonance, which is further proof of this mechanism.34 Additionally UV-stopped flow 
spectroscopy shows that the hemolysis is coupled to hydrogen atom extraction from 




Propionyl-CoA carboxylase requires biotin as a cofactor. Kogl first isolated biotin from 
egg white.36  The structure of biotin was determined in 1942.37 Biotin binds to the lysine 
of a well-defined binding site that has the sequence Ala-Met-Lys-Met.24, 38 Propionyl-
CoA carboxylase is biotinylated by holocarboxylase synthetase.39 
Methylmalonyl-CoA mutase requires cobalamin as a cofactor40, 41, 42; more 
specifically the mutase requires a form of cobalamin called adenosylcobalamin. 
Cobalamin was first determined to be of interest in 1926 when Minot and Murphy43 
successfully treated pernicious anemia with a diet that included crude liver extracts. Two 
decades later, crude liver extract was again examined, and cobalamin isolated.44 Rickes 
crystallized cobalamin from liver that same year, and also named it vitamin B12.45  The 
structure of cobalamin was determined soon after by electron density mapping.46 
Cobalamin has many forms, but only the form adenosylcobalamin acts as a cofactor for 
methylmalonyl-CoA mutase.25 The pathway from cobalamin to adenosylcobalamin was 
first described in Clostridium tetanomorphum, where it was also shown that magnesium 
was required.47 It was later confirmed that a similar pathway occurs in mammals, as was 
shown by looking at the liver and kidneys of rabbit, rat, and human.48 Kerwar also 
showed that cobalamin could be converted to adenosylcobalamin by HeLa cells, so long 
as they were cultured in the presence of ATP and in a reducing system.49 This set of 




GENE AND PROTEIN STRUCTURE 
In 1986, the cDNA for propionyl-CoA carboxylase was first isolated.50 Lamhonwah 
showed that the gene PCCA, responsible for propionyl-CoA carboxylase subunit α, was 
on chromosome 13; additionally, the gene PCCB, encoding propionyl-CoA carboxylase 
subunit β was on chromosome 3. This was further narrowed to PCCA being located at 
13q32, and PCCB at 3q22.51 They also noted that the α subunit mRNA was much larger 
than the β-subunit mRNA, with transcript lengths of 2.9 kb and 2.0 kb, respectively.  The 
following year, a partial cDNA sequence was published, which showed the sequence for 
the biotin binding site and an approximately 60 amino acid conserved region that 
included the biotin binding site.52 Other groups also published information gleaned about 
the individual subunits α53, 54 and β55, 56, 57, 58, 59, such as sequence fragments, amino acid 
length, exon boundaries, and pre- and post-processing size of the protein. The full cDNA 
sequence of each subunit was published soon after, which, for each, showed the complete 
structure of the 5’UTR, 3’UTR, and mitochondrial leader sequence.60 Additional studies 
showed that the two subunits had unequal rates of synthesis or degradation, with the β-
subunit being in excess.61 
The methylmalonyl-CoA mutase gene was cloned in 1988 from human placenta.62 
The next year, this data was confirmed by cloning cDNA from human liver.63  They 
showed that methylmalonyl-CoA mutase has a 742 amino acid open reading frame and a 
32 amino acid leader sequence. Methylmalonyl-CoA mutase was shown to be located on 
chromosome 6, in the p12-21.1 region.64, 65 The mutase is 13 exons long, and spans more 
than 35 kb of the genome. In 1986, Rosenberg also showed the mitochondrial targeting 
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sequence in detail, noting that it had a net positive charge, and that cleavage took place 
between a glutamine and an asparagine.66 The trafficking of methylmalonyl-CoA mutase 
into the mitochondria is modulated by an energy-dependent mechanism; once in the 
mitochondria it is quickly converted into its mature form.67 The presence or absence of 
adenosylcobalamin does not affect the localization of the mutase into the mitochondria.68 
The crystal structure of Propionibacterium shermanii shows that the C-terminal end is 
responsible for binding adenosylcobalamin, and the N-terminal end contains the 
homobinding domain.69 The crystal structure of Propionibacterium shermanii has also 
helped elucidate how the cobalt atom is coordinated in the enzyme,70  how 
methylmalonyl-CoA  if found in bound and unbound forms71, and what the structure 
looks like with and without a tyrosine at the active site72. 
 
CAUSE OF DISEASE STATES 
Deficiencies resulting in disease 
Cofactor deficiencies have been known to cause many different diseases. In the case of 
propionyl-CoA carboxylase, the cofactor is biotin. There is a report of experimental 
biotin deficiency73 induced by biotin sequestration by consuming large amounts of egg 
white.  The symptoms resulting from this diet were reversed with the application of 
biotin.  Because methylmalonic acidemia has a cobalamin-responsive form (discussed 
below), it was postulated by Hsia that there might be a biotin responsive form of 
propionic acidemia.74 However, there have been no reports of such a disease. 
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Methylmalonyl-CoA mutase requires the cofactor of adenosylcobalamin.  There 
have been reports of cobalamin deficiency leading to methylmalonic acidemia.ii, iii, 75 Most 
cases were readily reversed when cobalamin was administered, though some patients did 
not respond to cobalamin treatment. This result implicated methylmalonyl-CoA mutase 
as an additional location for metabolic defect, along with cobalamin deficiency.95 It was 
also reported that homocystinuria occurs in patients with cobalamin-responsive 
methylmalonic acidemia.76, 77 There has been one report of a child born with 
methylmalonic acidemia due to his vegetarian mother being cobalamin deficient during 
pregnancy.78 The child was returned to health after cobalamin was added to his diet. 
Genetic mutation resulting in disease 
Retrospectively, Childsi was the first to identify propionic acidemia as a new disease. 
This disease state was further confirmed in 1968.79  Studies used 14C labeled propionate 
and showed that there was an error in propionate metabolism in patient fibroblasts80 and 
leukocytesli. While propionyl-CoA carboxylase was clearly implicated as having a defect, 
this wasn’t confirmed genetically until 199081 when the first of a slew of mutations were 
reported.82, 83, 84, 85, 86 In the α-subunit, these mutations included 2 short insertion/deletions 
creating an exon skip, an insertion creating a premature stop codon, and mutations 
reducing the stability of the protein. In the β-subunit, mutations were found81, 87, 88, 59 that 
cause the deletion of 14 basepairs with the insertion of 12 basepairs that creates a 
premature stop codon, an insertion leading to a premature stop codon, splicing mutations, 
and a mutation causing an exon skip. There is evidence for interallelic complementation 
with respect to the β-subunit.89 The diversity in mutations that cause disease might be 
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responsible for the heterogeneity of symptoms and outcomes in propionic acidemia 
patients. Propionic acidemia is inherited in an autosomal recessive manner.90 
There have been reports of patients who have a genetic defect in the enzyme that 
biotinylates  propionyl-CoA carboxylase, holocarboxylase synthetase.  Holocarboxylase 
synthetase also biotinylates Acetyl-CoA carboxylases 1 and 2, 3-methylcrotonyl-CoA 
carboxylase, pyruvate carboxylase.91 Because holocarboxylase synthetase biotinylates 
these three additional enzymes, additional pathways are also affected. These patients 
have the disease multiple carboxylase deficiency.92 
There has been one report of a patient with a methylmalonyl-CoA racemase 
deficiency.93 This patient was restudied and confirmed to have a racemase mutation.94 
In methylmalonic acidemia, methylmalonyl-CoA mutase was implicated by Smith 
and Monty in 1959.40 This was further postulated in 196795 and 196896, when researchers 
came across patients with symptoms that were similar to cobalamin responsive patients, 
however, these new patients did not respond to cobalamin treatment.  Genetically, the 
first mutations were found in 1990 when cDNA was cloned and sequenced from a 
patient.97 Also that year, it was noted that the patients described to date did not have gross 
chromosomal rearrangements, large insertions or deletions, or mutations at restriction 
enzyme sites.98  Since then many mutations have been found throughout the gene that 
cause either a mut0 or mut- phenotype.99, 100, 101, 102, 103 Interestingly, there are some mut0 cell 
lines that were able to complement some, but not all, mut0 lines, giving evidence of 
interallelic complementation.104 Because methylmalonyl-CoA mutase from 
Propionibacterium shermanii shares 65% sequence identity with human methylmalonyl-
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CoA mutase, it can be used as a model to map mutations.105 As such, Thoma showed that 
of the 12 known mutations at the time, eight were in the C-terminal adenosylcobalamin 
binding domain, and four were in the N-terminal homobinding domain.69 More recently, a 
patient has been found with a mutation that results in a lack of targeting sequence for the 
protein.106 Lastly, all of the mutations reported are inherited in an autosomal recessive 
manner, as evidenced by roughly equal numbers of males and females affected and lack 
of direct parental transmission of the disease.95, 107 Many patients with methylmalonic 
acidemia are compound heterozygotes.108 
Early on, it was reported that in addition to mutase deficiencies, abnormalities in 
cobalamin synthesis could lead to clinically significant methylmalonic acidemia..109 Cox 
and Whiteii were the first to report on a patient whose symptoms were alleviated with 
cobalamin treatment. This was the first hint that cobalamin metabolism could lead to 
disease. Additional studies110, 111 were done that showed that the primary defect in certain 
methylmalonic acidemia patients was in cobalamin metabolism. Early on it was known 
that there was more than one step that was affected, as 2 patients were shown to have 
different rates of accumulation of adenosylcobalamin, while retaining similar 
methylmalonyl-CoA to succinate turnover.111 The first complementation tests showed that 
there were three complementation groups: cblA, cblB, and cblC.112 Later studies 
confirmed the presence of a fourth group, cblD.113 Further complementation tests showed 
that cblA and cblC are mutants for NADPH- and NADH-aquacobalamin reductases.114  
The cblB complementation group results from mutations in the cob(I)alamin 
adenosyltransferase.115 Complementation tests have shown that there is some interallelic 
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complementation within the cblA group.116  cblA, cblB, and cblC mutations are also 
inherited in an autosomal recessive manner.107 More recently, cblF has been described.117 
However, due to low patient numbers in the cblD and cblF groups, the mode of 




Propionic acidemia was first described as ketotic hyperglycinemia.1 This patient118, 119, 120, 
121, and his sister122 who was similarly affected, were studied extensively. The primary 
manifestations in these patients were vomiting, lethargy, ketosis, and hyperglycinemia. 
However, additional patients didn’t consistently have the symptoms of ketosis123, 
metabolic acidosis124 or hyperglycinemia. In 1971, it was determined that ketotic 
hyperglycinemia and propionic acidemia were the same disease, and that the clinical 
presence of propionic acid, not ketosis or hyperglycinemia, was diagnostic for the 
disease.125 A study of 65 cases revealed that the most common clinical symptoms were 
feeding difficulties, lethargy, and hypotonia, with less common symptoms of seizures, 
coma, and hepatomegaly, among others.90 The hepatomegaly is due primarily to fat 
accumulation.79 Long-term consequences include heart disease, metabolic stroke, 
pancreatitis, blindness, and hearing loss. 
While propionic acidemia classically presents in the neonatal period, there are 
cases of “late onset” disease. Sutrees126 compared those who presented early (within the 
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first week of life) with those who presented later (sixth week of life or later), and made 
the following observations. There was a higher death rate in the early onset group than 
the late onset group, each early onset patient had an IQ of less than 60 and many needed 
dialysis. In contrast, each of the late onset patients had an IQ of greater than 60, and 
movement disorders were common. Both groups had roughly equal proportion of patients 
with chorea and dystonia. 
Patients with propionic acidemia have an characteristic biochemical profile 
including methylcitrate, propionylglycine, and 3-hydroxypropionate. Methylcitrate has 
been identified as a metabolite that was seen in patient, but not control populations.127 
Additionally, 3-hydroxypropionate has also been seen, which is likely a result of β-
oxidation of propionate.128 Tiglic aciduria has also been seen in patient samples.129 
Hyperammonemia is a common finding, and also correlates with propionic acid levels in 
serum.130 It has been suggested that the hyperammonemia is due to propionic acid 
inhibiting ureagenesis when ammonia is the substrate.131 More specifically, it has been 
suggested that the hyperammonemia is either due to depletion of N-acetyl glutamate, 
which, in turn, is attributable to depletion of acetyl-CoA or it is due competitive 
inhibition by propionyl–CoA of N-acetyl glutamate synthetase.132 The latter hypothesis 
has been supported by additional studies.133 
There are other interesting, but inconsistent, findings in patients with propionic 
acidemia. Neurologic symptoms are common.134 There are reports of fatal symmetric 
necrosis of the basal ganglia.124, 135 Additionally, there was a report of delayed neuronal 
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myelination upon inspection with an MRI.136 One patient was also reported to have 
parathyroid hormone resistance and B-cell lymphopenia.137  
Alternatively, there have are reports of propionyl-CoA carboxylase deficiencies in 
people who are asymptomatic.  Wolf reported on a child whose propionyl-CoA 
carboxylase deficiency was not found until she was 13, when her brother was found to be 
symptomatic.  While her urine did not have an abnormal organic acid profile, her 
fibroblasts were shown to have less than 10% enzyme activity.138 This is contrasted with 
a boy who was discovered after an affected sibling was found. His cultured fibroblasts 
showed only 3% enzyme activity, and he was found to excrete methylcitrate, 3-
hydroxypropionate, and glycine similar to his brother and other propionic acidemia 
patients.139 
Methylmalonic Acidemia 
Methylmalonic acidemia, the symptom, was first described in patients who had 
pernicious anemia, though pernicious anemia was a defect in cobalamin uptake and is 
distantly related to methylmalonic acidemia, the disease. Oberholzer showed that his 
patient excreted amounts of methylmalonic acid far in excess of pernicious anemia 
patients, and postulated that his patient had a new disease, which turned out to be 
methylmalonic acidemia due to a mutation in methylmalonyl-CoA mutase.95 This was in 
contrast to cobalamin-responsive patients who had defects in cobalamin metabolism. 
However, cobalamin-responsive or not-responsive patients had similar symptoms. The 
two forms of the disease, cobalamin responsive and non-responsive, were described by 
Morrow in 1969.140 He also stated that methylmalonic acid excretion was the hallmark of 
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this disease, and what differentiated it from ketotic hyperglycinemia (propionic 
acidemia). While methylmalonic acid excretion is a definitive diagnostic indicator for 
methylmalonic acidemia, studies show that excretion levels do not correlate with the 
clinical status of patients.141 
Patients with methylmalonic acidemia present very similarly to patients with 
propionic acidemia.  Symptoms include lethargy, failure to thrive, vomiting, dehydration, 
respiratory distress, hypotonia, and hepatomegaly.107 More recently, patients with renal 
failure have been reported.142, 143 As with propionic acidemia, neurologic symptoms have 
been reported in methylmalonic acidemia.144, 145  Pancreatitis is also a chronic feature of 
this disease.146  As noted earlier, there are two forms of methylmalonic acidemia due to 
methylmalonyl-CoA mutase defects, mut0 and mut -. Patients with mut0 mutations have a 
more severe disease course, and a higher death rate than mut – patients.147 
Methylmalonic acidemia patients who have cobalamin metabolism deficiencies 
have similar presentation to patients with methylmalonyl-CoA mutase deficiencies, but 
usually have a later onset, less mortality, and less severe course of disease.147 
Biochemically, methylmalonic acidemia patients are also similar to propionic 
acidemia patients. Again, methylcitrate and 3-hydroxypropionate are seen,127, 128 as well 
as propionic acid148 and its derivatives.149 Additionally, methylmalonic acid is an inhibitor 
of the malate-phosphate exchange, which may be responsible for the common findings of 
hyperglycemia and ketonemia.150 Because ketotic hyperglycinemia is seen in both 
methylmalonic acidemia and propionic acidemia, it must be a secondary effect of CoA 
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metabolism.151 Glutathione deficiency may contribute to lactic acidosis during 
decompensation episodes.152 
As with propionic acidemia, there have been reports of children with defects in 
methylmalonyl-CoA mutase and high methylmalonic acid levels who are 
asymptomatic.153, 154 All of these children were reported to have normal growth and 
development. Alternately, there was a report of a patient with “mild” methylmalonic 
acidemia, that is low-to-normal methylmalonic acid excretion, who had acidotic episodes 
and ketosis with hyperammonemia. Lastly, there have also been reports of children who 
have low-to-moderate methylmalonic acid excretion, as picked up by newborn screening, 
which usually resolved within two years of age.155 Of those with persistent 




Propionic acidemia and methylmalonic acidemia are usually diagnosed by 
measurement of their respective primary metabolite in urine or blood samples.  However, 
prenatal testing has become available for both of these genetic disorders. 
Propionic acidemia was first successfully diagnosed prenatally using cultured 
amniotic cells.156 Propionyl-CoA carboxylase activity was not found in this culture, 
which was later confirmed using fibroblasts.  Later, methylcitrate was used as a 
diagnostic marker in amniotic fluid.157 Again, this was confirmed using propionyl-CoA 
carboxylase activity in cultured cells.  Later, another prenatal diagnosis was made and 
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confirmed using chorionic villi.158 Even more recently, acylcarnitines in amniotic fluid 
have been used as a diagnostic tool.159 
Methylmalonic acidemia was similarly diagnosed successfully in utero. Morrow 
first detected methylmalonic acid in maternal urine and used that as evidence for a 
diagnosis.160 This diagnosis was confirmed at birth. He later used 14C incorporation in 
amniotic fluid cells to make a correct diagnosis.161 Mahoney similarly used cultured 
amniotic fluid cells, but also showed that amniotic fluid methylmalonic acid 




With prenatal diagnosis comes the opportunity to start treatment. There have not been 
any reports of propionic acidemia being treated in utero.  However, prenatal treatment of 
cobalamin responsive methylmalonic acidemia has been the subject of a few studies. In 
1975, large doses of adenosylcobalamin were prescribed after culture of amniotic cells 
indicated a defect in cobalamin synthesis.163 Additionally, another fetus, diagnosed in the 
third trimester responded well to large doses of adenosylcobalamin, as measured by 
maternal methylmalonic acid concentration.164 
 Patient treatment 
Traditionally, the goals of propionic acidemia treatment were to lower propionic acid 
levels, and regulate ammonia, glycine, and alanine levels. Peritoneal dialysis has been 
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used to successfully ameliorate some biochemical symptoms, such as hyperammonemia, 
of propionic acidemia.165 Diet is an important source of controlling propionate precursors. 
As such, parenteral nutrition can be useful to control intake when the patient is having a 
metabolic crises.166  When patients are not under metabolic stress, maintenance treatment 
options include protein restriction, biotin supplementation167 and L-carnitine 
supplementation.168 L-carnitine supplementation has been shown to increase the 
formation and excretion of short chain acylcarnitines and patients who were treated 
improved clinically.169 Another study of carnitine supplementation in conjunction with 
glycine showed an increase in tolerated protein, increased weight, development, and 
muscle tone, while showing a decrease in ketosis and hyperammonemia.170 Another 
option is antibiotic treatment to reduce the amount of propionate from anaerobic gut 
bacteria.171 In all patients, metronidazole was shown to reduce propionic acid excretion, 
and clinical improvement was seen in three of nine patients in this study.  
Methylmalonic acidemia patients are treated similarly to propionic acid patients. 
Restriction of natural protein has been shown to require non-branch chain amino acid 
supplementation if the restriction is severe.172 Cobalamin is administered to those patients 
who have cobalamin-responsive disease. With protein restriction and cobalamin doses, 
patients have done well.173 L-carnitine has also been prescribed for methylmalonic 
acidemia patients.169 In one patient who took supplemental carnitine, hippurate, which is 
a measure of mitochondrial ATP and CoA availability, increased along with a decrease in 
methylmalonyl and methylcitrate excretion.174 Antibiotic treatment has also been used to 
reduce the propionate formed by natural flora, and subsequently, methylmalonic acid 
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excretion levels.175 An additional antibiotic study showed decreases in 
hydroxypropionate, methylcitrate, and odd-chain fatty acid levels.176 
Treatment of both acidemias has been largely supportive, and future studies 
should focus on finding improvements that impact patient health.  Additionally, while the 
traditional method of restricting diet while administering carnitine and antibiotics has 
improved patient health177, there is still a high probability of long-term complications.178  
20 
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